Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 4(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05492695Phase 4Terminated

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

Role: lead

NCT00471952Phase 3Completed

Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache

Role: lead

NCT00399243Phase 4Unknown

Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache

Role: lead

NCT00300924Phase 3Completed

A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine

Role: lead

All 4 trials loaded